A placebo-controlled randomized cross-over lovastatin trial in neurofibromatosis type 1 reveals Ras/MAPK modulation of dynamic emotional face processing

Abstract

Neurofibromatosis type 1 (NF1) is a neurodevelopmental disorder characterized by cognitive and socioemotional processing deficits, associated with dysregulation of the Ras/MAPK pathway and alterations in neural inhibition and the GABA system.